GENE-WIDE REPLICATION STUDY OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) WITH SCHIZOPHRENIA: POPULATION BASED ASSOCIATION ANALYSIS AND META-ANALYSIS

2008 ◽  
Vol 102 (1-3) ◽  
pp. 187
Author(s):  
Kunihiro Kawashima ◽  
Masashi Ikeda ◽  
Taro Kishi ◽  
Tsuyoshi Kitajima ◽  
Yoshio Yamanouchi ◽  
...  
Keyword(s):  
Association Analysis ◽  
Neurotrophic Factor ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Population Based ◽  
Replication Study

The Influence of Val66Met Polymorphism in Brain-Derived Neurotrophic Factor on Stroke Recovery Outcome: A Systematic Review and Meta-analysis

2021 ◽  
pp. 154596832110141
Author(s):  
Xuan Liu ◽  
Jun-Chao Fang ◽  
Xin-Yue Zhi ◽  
Qiu-Yu Yan ◽  
Hong Zhu ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Genetic Model ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Recessive Model ◽  
Stroke Recovery ◽  
Stroke Severity ◽  
Val66met Polymorphism ◽  
Asian Patients ◽  
Caucasian Patients

Background and purpose. A single nucleotide polymorphism at nucleotide 196 (G/A) in the human brain-derived neurotrophic factor ( BDNF) gene produces an amino acid substitution (valine to methionine) at codon 66(Val66Met). It is unclear whether carriers of this substitution may have worse functional outcomes after stroke. We aimed to explore the distribution of Val66Met polymorphism and evaluate the effect of different genotypes on stroke functional recovery. Methods. Several databases were searched using the keywords BDNF or brain-derived neurotrophic factor, codon66, G196A, rs6265, or Val66Met, and stroke. Results. A total of 25 articles were relevant to estimate the distribution of alleles; 5 reports were applied in the meta-analysis to assess genetic differences on recovery outcomes. The genetic model analysis showed that the recessive model should be used; we combined data for AA versus GA+GG (GG—Val/Val, GA—Val/Met, AA—Met/Met). The results showed that stroke patients with AA might have worse recovery outcomes than those with GA+GG (odds ratio = 1.90; 95% CI: 1.17-3.10; P = .010; I2 = 69.2%). Overall, the A allele may be more common in Asian patients (48.6%; 95% CI: 45.8%-51.4%, I2 = 54.2%) than Caucasian patients (29.8%; 95% CI: 7.5%-52.1%; I2 = 99.1%). However, in Caucasian patients, the frequency of the A allele in Iranians (87.9%; 95% CI: 83.4%-92.3%) was quite higher than that in other Caucasians (18.7%; 95% CI: 16.6%-20.9%; I2 = 0.00%). Conclusion. Val66Met AA carriers may have worse rehabilitation outcomes than GA+GG carriers. Further studies are needed to determine the effect of Val66Met polymorphism on stroke recovery and to evaluate this relationship with ethnicity, sex, age, stroke type, observe duration, stroke severity, injury location, and therapies.

Brain-derived neurotrophic factor in substance use disorders: A systematic review and meta-analysis

2018 ◽  
Vol 193 ◽  
pp. 91-103 ◽  
Author(s):  
Felipe Ornell ◽  
Fernanda Hansen ◽  
Felipe Barreto Schuch ◽  
Fernando Pezzini Rebelatto ◽  
Ana Laura Tavares ◽  
...  
Keyword(s):  
Systematic Review ◽  
Substance Use ◽  
Substance Use Disorders ◽  
Neurotrophic Factor ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor

Circulating Brain-Derived Neurotrophic Factor as a potential biomarker in stroke: a Systematic review and Meta-analysis

2021 ◽  
Author(s):  
Helia Mojtabavi ◽  
Zoha Shaka ◽  
Sara Momtazmanesh ◽  
Atra Ajdari ◽  
Nima Rezaei
Keyword(s):  
Physical Training ◽  
Neurotrophic Factor ◽  
Neuronal Damage ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Blood Levels ◽  
Cerebrovascular Event ◽  
Medical Databases ◽  
Potential Biomarker ◽  
Significant Difference

Abstract Background Stroke, an acute cerebrovascular event, is a leading cause of disability, placing a significant psycho-socioeconomic burden worldwide. Neuroplasticity is adaptation and reorganization following neuronal damage. Brain-derived neurotrophic factor (BDNF) is a neurotrophin coordinating neuroplasticity after various neurological disorders such as stroke. Methods We conducted a systematic search in the main electronic medical databases through January 2021 and identified studies that measured blood levels of BDNF in patients with stroke. The primary aim was to compare BDNF levels between patients with stroke and healthy controls (HC). The secondary aims included investigation of (1) longitudinal changes in the BDNF levels post-stroke, (2) effects of physical training, (3) repeated transcranial magnetic stimulation (rTMS), and presence of depression on BDNF levels in patients with stroke. Results Among 6243 reviewed records from PubMed, Web of Science, and Scopus, 62 studies were eligible for inclusion. Subjects with stroke, n = 1856, showed lower BDNF levels compared to HC, n=1191 (SMD [95%CI] = -1.04 [-1.49 to -0.58]). No significant difference was detected in the level of BDNF through time points past stroke. BDNF levels were lower in the patients with depression compared to non-depressed subjects (SMD [95%CI] = -0.60 [-1.10 to -0.10]). Physical training had an immediate positive effect on the BDNF levels and not statistically significant effect in the long term; SMD [95%CI] = 0.49 [0.09 to 0.88]) and SMD [95%CI] = 0.02 [-0.43 to 0.47]). Lastly, rTMS showed no effect on the level of BDNF with 0.00 SMD. Conclusions This study confirms that stroke significantly affects the level of BDNF in various domains such as cognition, affect, and motor function. We believe that BDNF could be regarded as a valuable diagnostic biomarker for acute stroke and a potential prognostic biomarker for depression and cognitive deficits.

scholarly journals Association Between Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Methamphetamine Use Disorder: A Meta-Analysis

2020 ◽  
Vol 11 ◽  
Author(s):  
Li He ◽  
Yanhui Liao ◽  
Qiuxia Wu ◽  
Tieqiao Liu
Keyword(s):  
Neurotrophic Factor ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Current Data ◽  
Cochrane Library ◽  
Case Control Studies ◽  
Val66met Polymorphism ◽  
Asian Populations ◽  
Bdnf Val66met Polymorphism ◽  
Relationship Of

Background: Several studies had examined the association between brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and methamphetamine (METH) use disorder, whereas the results were conflicting. The aim of this study was to conduct a meta-analysis to achieve a pooled effect size of the association between BDNF Val66Met polymorphism and METH use disorder.Methods: Literature searches were conducted in PubMed, EMBASE, and Cochrane Library up to July, 2020. All relevant studies on the relationship of BDNF Val66Met polymorphism and METH addiction were retrieved. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated in the dominant, recessive, co-dominant, and allele model to appraise the association.Results: Seven case–control studies with a total of 2,204 subjects (956 METH-dependent cases and 1,248 healthy controls) were included in this meta-analysis. The results showed a significant correlation between BDNF Val66Met polymorphism and METH dependence in overall population under different genetic models. However, subgroup analysis indicated that the association only existed in Han Chinese but not in other Asian populations.Conclusion: Although the current data indicate that BDNF Val66Met polymorphism might be a potential genetic factor for METH use disorder, more researches are needed to prove its role in different populations.

Sign in / Sign up

Export Citation Format

Share Document